<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03678909</url>
  </required_header>
  <id_info>
    <org_study_id>H-42776</org_study_id>
    <nct_id>NCT03678909</nct_id>
  </id_info>
  <brief_title>Cardiac Biomarkers in Patients With Single Ventricle Physiology</brief_title>
  <official_title>Cardiac Biomarkers in Patients With Single Ventricle Physiology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Baylor College of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      All neonates with congenital heart disease undergoing stage one palliation (Norwood
      procedure, Damus-Kaye-Stansel procedure) at Texas Children's Hospital will be regularly
      monitored for B-type natriuretic peptide (BNP) and Troponin level before the surgical
      procedure, on arrival to the cardiac intensive care unit after their surgical procedure,
      every 6 hours during the first 24 hours of the post-operative period, followed by daily
      levels for the first week, and then weekly during patient's regular laboratory work up
      schedule.

      These cardiac biomarkers are linked to demographic, hemodynamic, respiratory, pharmacological
      data available via Sickbay.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All neonates with congenital heart disease undergoing stage one palliation (Norwood
      procedure, Damus-Kaye-Stansel procedure) at Texas Children's Hospital will be regularly
      monitored for B-type natriuretic peptide (BNP) and Troponin level before the surgical
      procedure, on arrival to the cardiac intensive care unit after their surgical procedure,
      every 6 hours during the first 24 hours of the post-operative period, followed by daily
      levels for the first week, and then weekly during patient's regular laboratory work up
      schedule.

      These cardiac biomarkers are linked to demographic, hemodynamic, respiratory, pharmacological
      data available via Sickbay.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2018</start_date>
  <completion_date type="Anticipated">May 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>3- 6 months depending on second stage procedure</time_frame>
    <description>Mortality up to anticipated Glenn Procedure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>NEC</measure>
    <time_frame>3- 6 months depending on second stage procedure</time_frame>
    <description>Incidence of Necrotizing enterocolitis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reintubation</measure>
    <time_frame>3- 6 months depending on second stage procedure</time_frame>
    <description>Incidence of Reintubation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cath intervention</measure>
    <time_frame>3- 6 months depending on second stage procedure</time_frame>
    <description>Incidence of cath interventions</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Hypoplastic Left Heart</condition>
  <condition>Congenital Heart Disease</condition>
  <condition>Cyanotic Congenital Heart Disease</condition>
  <condition>Cardiac Disease</condition>
  <arm_group>
    <arm_group_label>Hypoplastic Left Heart Disease</arm_group_label>
    <description>Patients with congenital hypoplastic left heart disease who will undergo surgical palliation with Norwood procedure or DKS or Damus-Kaye-Stansel procedure</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Norwood Palliation / DKS / Damus-Kaye-Stansel procedure</intervention_name>
    <description>Norwood Palliation / DKS / Damus-Kaye-Stansel procedure</description>
    <arm_group_label>Hypoplastic Left Heart Disease</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Neonate with Hypoplastic Left Heart Syndrome
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Clinical diagnosis of Hypoplastic Left Heart Syndrome as congenital heart disease as a
        neonate

        Exclusion Criteria:

        Other diagnosis of congenital heart disease than Hypoplastic Left Heart Syndrome Patients
        older than 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>2 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc M Anders, ND</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marc M Anders, MD</last_name>
    <phone>832-824-1000</phone>
    <email>marc.anders@bcm.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc M Anders, MD</last_name>
      <phone>832-824-1000</phone>
      <email>marc.anders@bcm.edu</email>
    </contact>
    <investigator>
      <last_name>Raysa C Morales Demori</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeffrey S Heinle</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>September 16, 2018</study_first_submitted>
  <study_first_submitted_qc>September 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 20, 2018</study_first_posted>
  <last_update_submitted>July 8, 2019</last_update_submitted>
  <last_update_submitted_qc>July 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baylor College of Medicine</investigator_affiliation>
    <investigator_full_name>Marc Anders</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Troponin</keyword>
  <keyword>BNP</keyword>
  <keyword>Biomarkers</keyword>
  <keyword>Hypoplastic Left Heart</keyword>
  <keyword>Norwood</keyword>
  <keyword>DKS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Heart Defects, Congenital</mesh_term>
    <mesh_term>Hypoplastic Left Heart Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The data is blinded to other study investigators.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

